RT Journal Article
SR Electronic
T1 Predictors of second-line antiretroviral treatment virological failure at Felege hiwot and University of Gondar comprehensive specialized hospitals Amhara region, Northwest Ethiopia: a case-control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.20.23292946
DO 10.1101/2023.07.20.23292946
A1 Wubetu, Getahun Ayenew
A1 Ambelie, Yeshambel Agumas
A1 Shibabaw, Tebkew
A1 Getaneh, Gebremariam
A1 Abate, Michael Getie
YR 2023
UL http://medrxiv.org/content/early/2023/07/25/2023.07.20.23292946.abstract
AB Background Second-line HIV treatment failure has become increasing worldwide, mainly in sub- Sahara Africa including Ethiopia. Even though the problem becomes increasing, inadequate information was available about its magnitude and predictors in the current study area.Objective To assess the predictors of second line Anti-Retroviral Treatment virological failure among second line ART users.Method and materials Institutional based unmatched case control study design was conducted from first September 2021 to December last 2021 at Felege Hiowt and University of Gondar Comprehensive Specialized Hospitals; Amhara region, Northwest Ethiopia. A total of 216 patients (60 cases and 156 controls) were recruited by Simple random sampling technique with 1:3 cases-to-controls ratio. Patients who had two viral load results >1000 copies/ml within a 3-month interval after taking ART drugs for at least 6 months were cases whereas ≤1,000 copies/ mL were controls. The sample size was calculated by using Epi-Info version 7.2.4. Structured questionnaires were used to gather the required information. SPSS version 26 was used to summarize the findings. In bivariate logistic regression model, Variables with two-tailed P-value ≤ 0.25 at 95% confidence interval were transferred into multivariate binary logistic regression mode and P value at ≤ 0.05 was set as statistically significant.Results Out of 216 patients recruited, 212 were participated with a response rate of 98.2%. Among the participants, 117 (55.2%) were males and 187 (88.2%) were urban dwellers. 208 (98.1%) of the respondents had age > 24 years, 73 (34.4%) had elementary level of education, 72(34%) had poor ART adherence and 112(52.8) did not disclose their HIV status. Likewise, most of the patients 147(69.37) didn’t used condom. The Predictors were not disclosing HIV status (AOR=3.4, 95% CI: 1.52 – 7.79), poor adherence level (AOR=5.27, 95% CI: 2.2 - 12.5), not using condom (AOR=4.47, 95% CI: 1.63 – 12.2) and high Viral load (>1000 copes/ml) when switched to second line ART (AOR=3.56, 95% CI: 1.5 - 8).Conclusion and recommendations The Predictors of second line Anti-Retroviral Treatment virological failure were non-disclosure, poor adherence, not using condom and high Viral load (>1000 copes/ml) at switched to second line ART. Disclosing their HIV status, using condom and improving their adherence level for patients and counselling about the importance of disclosure and good adherence for health care providers are crucial.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was obtained from Bahir Dar University, College of Medicine, and Health Sciences Institutional Review Board (IRB).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files